You are here

Article Text

Article menu
Download PDFPDF
Letter
Subcutaneous furosemide in patients with refractory heart failure
  1. Ainara Lozano Bahamonde,
  2. Vanessa Escolar Pérez,
  3. Alain Laskibar Asua,
  4. María Rodríguez Rodríguez and
  5. Nekane Murga Eizagaechevarria
  1. Department of Cardiology, Organizacion Sanitaria Integrada Bilbao Basurto, Bilbao, Spain
  1. Correspondence to Ainara Lozano Bahamonde, Organizacion Sanitaria Integrada Bilbao Basurto, Bilbao 48013, Spain; ainaralozano{at}hotmail.com

https://doi.org/10.1136/bmjspcare-2018-001570

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Resistance to oral diuretics limits the optimisation of diuretic treatment in patients with congestive heart failure (HF).1 2 Publications on the use of subcutaneous furosemide for treatment of HF are scarce, not being experience regarding its use as long-term treatment.3–5

    Methods

    We carried out a descriptive study based on the follow-up of patients with HF and congestive decompensations in our hospital from October 2014 to May 2018 with subcutaneous furosemide administrated by elastomeric pumps. The inclusion criteria were patients with decompensated HF without response to oral diuretics, frequent hospital admissions or repetitive use of intravenous treatment at home. The …

    View Full Text

    Footnotes

    • Contributors ALB: original idea, planning, conception and design, patient recruitment, statistical analysis. VE: planning, conception and design, patient recruitment, acquisition of data, completion of source documents, reporting. AL and MR: evaluation of end points and confirmation of inclusion and exclusion criteria. NM: conduct and interpretation of data.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval CEIC.

    • Provenance and peer review Not commissioned; internally peer reviewed.